Bausch + Lomb (NYSE:BLCO) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Bausch + Lomb (NYSE:BLCO) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $23.00 price target on the stock. HC Wainwright also issued estimates for Bausch + Lomb’s Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.23 EPS, Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.27 EPS and FY2025 earnings at $0.91 EPS.

A number of other analysts have also commented on BLCO. Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Royal Bank of Canada cut their target price on Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Wednesday, January 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, October 31st. Stifel Nicolaus lowered their price objective on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday, January 29th. Finally, Wells Fargo & Company reduced their target price on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Bausch + Lomb has an average rating of “Hold” and a consensus target price of $19.83.

Bausch + Lomb Price Performance

NYSE BLCO opened at $15.92 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of -15.16, a PEG ratio of 2.18 and a beta of 0.46. The business has a 50 day simple moving average of $17.42 and a 200 day simple moving average of $18.13. Bausch + Lomb has a 52-week low of $13.16 and a 52-week high of $21.69.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.02. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 earnings per share. Analysts anticipate that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Alberta Investment Management Corp increased its position in Bausch + Lomb by 36.0% during the fourth quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company’s stock worth $54,328,000 after buying an additional 796,400 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Bausch + Lomb during the 4th quarter worth approximately $14,122,000. King Street Capital Management L.P. bought a new position in shares of Bausch + Lomb during the 3rd quarter worth approximately $14,122,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Bausch + Lomb by 51.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company’s stock worth $21,996,000 after acquiring an additional 414,138 shares during the last quarter. Finally, Barclays PLC bought a new stake in Bausch + Lomb in the 3rd quarter valued at $5,797,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.